A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels
Gut and Liver
;
: 528-534, 2017.
Article
in English
| WPRIM
| ID: wpr-88943
ABSTRACT
BACKGROUND/AIMS:
Hepatocellular carcinoma (HCC) can develop in chronic hepatitis B (CHB) patients with normal alanine aminotransferase (ALT) levels. Therefore, methods that can stratify an individual's HCC risk are needed.METHODS:
A simple HCC risk score was developed from 971 patients with CHB who had elevated hepatitis B virus DNA levels (>2,000 IU/mL) with normal or mildly elevated ALT levels (<80 U/L). The score was validated from an independent cohort of 507 patients.RESULTS:
A 4-point risk scale was developed, with HCC risk ranging from 0% to 17.8% at 5 years for the lowest and highest risk scores. The D2AS score had high area under the receiver operating curves (AUROCs) for predicting development of HCC at 3/5 years (0.895/0.884). The calculated AUROCs to predict the development of HCC at 3/5 years were 0.889/0.876 in the validation cohort, with 5-year HCC incidence rates ranging from 0% to 13.8% at 5 years for the lowest and highest risk scores.CONCLUSIONS:
The D2AS risk score can play a valuable role in risk stratification and may be useful for guiding clinical decisions for enhanced surveillance or treatment to reduce the HCC risk in CHB patients with normal or mildly elevated ALT levels.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
DNA
/
Hepatitis B virus
/
Incidence
/
Cohort Studies
/
Carcinoma, Hepatocellular
/
Hepatitis B, Chronic
/
Alanine
/
Alanine Transaminase
/
Hepatitis B
/
Hepatitis, Chronic
Type of study:
Etiology study
/
Incidence study
/
Observational study
/
Prognostic study
/
Risk factors
Limits:
Humans
Language:
English
Journal:
Gut and Liver
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS